HOME >> BIOLOGY >> NEWS
Common asthma drug saves patients money, trips to hospital

s. Patient data was used only if the patient hadn't taken any of the three drugs for the first nine months, followed by nine months of using one of the prescribed medications.

"Our findings are based on real-world data," Pathak said. "We analyzed the data after doctors had already prescribed one of the three drugs to their patients."

Patient data was split into three groups, based on the drug prescribed: 284 patients used fluticasone propionate in either 0.044 or 0.110 milligram doses; 302 used montelukast in 5 and 10 milligram doses; and 195 used zafirlukast in 20 milligram doses. The latter two drugs were taken in tablet form.

The average total cost of asthma care for a patient using fluticasone propionate during the nine-month period was $528. The cost was nearly double for montelukast users ($967), and it nearly tripled for zafirlukast users ($1,359). Total cost included filling prescriptions, trips to doctors' offices and emergency rooms, hospitalizations and the need for additional medication to control asthma symptoms.

The use of fluticasone propionate was also linked to fewer hospitalizations and less of a need for additional medication to control asthma symptoms - the data showed that patients could get by longer on a regimen of fluticasone propionate alone.

"An inhaled corticosteroid, which fluticasone propionate is, should be considered the first line of therapy in patients with symptoms of
'"/>

Contact: Dev Pathak
Pathak.1@osu.edu
614-688-3956
Ohio State University
10-Apr-2002


Page: 1 2 3 4

Related biology news :

1. Common cold virus can cause polio in mice when injected into muscles
2. Common call for action on European Research Council (ERC)
3. Common therapy for HIV associated with cervical abnormality regression
4. Common chemicals morphing into potential toxins in Arctic
5. Common worm provides insights into salmonella virulence
6. Common virus may contribute to uncommon bone disease in children
7. Common airborne substance makes asthmatics more sensitive to house dust mites: study
8. Common genetic damages in non-dividing cells lead to the creation of mutant proteins
9. Common nutrients fed to pregnant mice altered their offsprings coat color
10. Common treatment for depression is safe and effective for Alzheimers patients
11. Common gene variant increases risk of atherosclerosis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Common asthma drug saves patients money trips hospital

(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... to pre-order customers the first week of May, 2015 ... month of May. Gino Pereira ... milestone for the company as Wocket® enters the consumer ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
(Date:5/27/2015)... , May 26, 2015 Research and ... the "Global Breast Cancer Monoclonal Antibodies Market ... Globally, Roche seems to dominate the breast ... Its block buster molecule, Herceptin has been able ... was found that breast cancer cells become recalcitrant ...
(Date:5/27/2015)... 27, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today ... 2015. Aviv Boim , CEO ... work to generate functional specific antibodies, targeting identified cancer ... are encouraged by the development progress. We are excited ... which modulate immune checkpoints gain clinical acceptance for cancer ...
(Date:5/27/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ... therapies for cancer, announced today that Dr. Marnix ... will be making an Industry Expert Theater Presentation at ... on Saturday, May 30, 2015, from 3 ... in McCormick Place. Dr. Bosch will provide ...
(Date:5/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... status of the Company,s Series A and Series ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO At March ... of Series A Preferred Stock and Series A-1 ...
Breaking Biology Technology:Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3
Cached News: